N/A Intensive care unit, Critical care, Ventilators, Mechanical
Conditions
Interventions
Group A: 2 ml of 2% lidocaine administered over the cuff every 6 hours for 24 hours (160 mg/24 hours)
Group B: 4 ml of 4% lidocaine administered over the cuff every 6 hours for 24 hours (640 mg/24 ho
Anesthesia, Local
Lidocaine, Pain Management
Sponsors
Homma Hiroshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Intubated patients in ICU, CCU, EICU Patients Patients aged between 18 and 85 years Patients with CPOT 2 or more Patients for whom consent has been obtained.
Exclusion criteria
Exclusion criteria: Patients with GCS 8 or less Patients who are expected to be extubated within 24 hours. Patients who have been previously enrolled in this study Patients with a known allergy to lidocaine Patients who need to be arrested, detained, detained, or confined by investigative or legal authorities Patients participating in clinical research involving other therapeutic interventions within the last three months Patients whose participation in the study is deemed inappropriate by the clinician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Absolute value of the CPOT score, 30 minutes after the start of the intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| CPOT scores at 2, 4 and 6 hours after the start of the intervention Dose of drugs used for analgesia and sedation at 24 hours after the start of the intervention Onset of delirium up to 72 hours after the start of the intervention Ventilator-associated pneumonia (VAP) up to 7 days after the end of the intervention Ventilator free days at 28 days from the start of the intervention Lidocaine concentration in blood 15-30 minutes after the last intervention (at 18 hours). Percentage of lidocaine intoxication during the intervention. | — |
Contacts
Public ContactKeiichiro Shimoyama
Tokyo Medical University Hospital
Outcome results
None listed